AKB-6899

• Description:

  AKB-6899, a prolyl hydroxylase domain 3 (PHD3) inhibitor, is a selective HIF-2α stabilizer. AKB-6899 also increases soluble form of the VEGF receptor (sVEGFR-1) production from GM-CSF-treated macrophages, and has antitumor and antiangiogenic effects[1].

• Product Name Alternative:

  KPT-8602 (Z-isomer), CL29926; (±)-Imazamox, MKC242 (free base), MKC250

• UNSPSC:

  12352005

• Target:

  HIF/HIF Prolyl-Hydroxylase

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/akb-6899.html

• Concentration:

  10mM

• Purity:

  99.95

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O=C(CNC(C1=NC=C(C=C1O)C2=CC=CC(F)=C2)=O)O

• Molecular Formula:

  C14H11FN2O4

• Molecular Weight:

  290.25

• References & Citations:

  [1]Julie M Roda, et al. Stabilization of HIF-2α induces sVEGFR-1 production from tumor-associated macrophages and decreases tumor growth in a murine melanoma model. J Immunol. 2012 Sep 15;189 (6) :3168-77.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [1007377-55-0]